免疫激活与化疗联合检查点阻断在三阴性乳腺癌中的演变。

Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer.

机构信息

Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA.

Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA; Ludwig Center at Harvard, Boston, MA 02115, USA.

出版信息

Cancer Cell. 2021 Dec 13;39(12):1562-1564. doi: 10.1016/j.ccell.2021.11.001. Epub 2021 Nov 11.

DOI:10.1016/j.ccell.2021.11.001

PMID:34767761

Abstract

Immune checkpoint blockade plus chemotherapy is emerging as a standard treatment for some patients with triple-negative breast cancer (TNBC). In this issue of Cancer Cell, Zhang et al. employ extensive single-cell immune compartment analyses of pre- and post-therapy TNBC, and they reveal potential mechanisms of T cell activation and patterns of immune evolution that may inform future biomarkers of response and clinical benefit.

摘要

免疫检查点阻断联合化疗正在成为某些三阴性乳腺癌（TNBC）患者的标准治疗方法。在本期《癌细胞》杂志中，Zhang 等人对 TNBC 患者治疗前后的单细胞免疫区室进行了广泛分析，揭示了 T 细胞激活的潜在机制和免疫进化模式，这些可能为预测治疗反应和临床获益的生物标志物提供信息。